Business
Imaging3 Announces the Signing of an Agreement with Halteres Associates
Imaging3 Announces the Signing of an Agreement with Halteres Associates.
About this update from Grapefruit Usa Inc.
[{"type":"text","content":"\n\n Burbank, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB: IGNG), a development stage company targeting disruptive technologies in the medical imaging industry, is pleased to announce the signing of an agreement with Halteres Associates (Emeryville, CA), a leading bioscience consultancy with extensive, long-term, direct operating experience in a broad spectrum of health sciences disciplines, including the development and commercialization of medical devices and diagnostics.   \n “We are very excited to have the support of Halteres Associates, during this critical push for FDA review and preparation for commercialization.  They bring tremendous operating experience and are involved in many potential market sectors of interest to the Company,” said CEO, John Hollister. The founding and managing partners at Halteres, Mickey Urdea, Ph.D. and Rich Thayer, MBA, will apply their insights, knowledge and network to Imaging3 by providing commercial analysis, regulatory and reimbursement strategy, operational efficiency and financing advice.  For more than a decade much of their work has involved development of improved diagnostic techniques worldwide and the utilization of the data derived from these technologies.  Their work has been in conjunction with many global healthcare organizations with the potential to collaborate with Imaging3. Prior to Halteres, Dr. Urdea founded and served as chief executive officer of Tethys Bioscience, a proteomics-based diagnostics company that has been involved in the prevention of type-2 diabetes (assets acquired by HDL), and was chief executive officer of Quantum Dots Corporation (assets acquired by Life Technologies).  He successfully raised more than $100MM in order to finance these companies. Additionally, Dr. Urdea is a founder and the chairman of Catalysis Foundation for Health (CFH), a non-profit organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. Prior to his current activities, Dr. Urdea founded the Nucleic Acid Diagnostics business at Chiron Corporation, where he pioneered viral load assays for the human hepatitis B, hepatitis C and immunodeficiency viruses. Dr. Urdea is an author on over 200 peer-reviewed scientific publications and has more than 125 issued and pending patents....